1.Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007; 69(18): 1789–99.
2. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc (7).nbib. 2005; 53(4): 695–9.
3. Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry. 2007 ; 52(5): 329–32.
4. Lescure FX, Omland LH, Engsig FN, et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: A Danish nation wide cohort study. Clin Infect Dis. 2011; 52(2): 235–43.
5. D’Arminio Monforte A, Cinque P, Mocroft A, et al. Changing Incidence of Central Nervous System Diseases in the Euro SIDA Cohort. AnnNeurol. 2004; 55(3): 320–8.
6. Lifford DB. Human immunodeficiency virus-associated dementia. ArchNeurol 2000; 57:321–24
7. Mocatest.org [homepage on the internet]. Nasreddine Z. [updated 2019, cited 23 feb 2021]. Available from http://www.mocatest.org.
8.Suarez S, Baril L, Stankoff B, et al. Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. AIDS. 2001; 15(2): 195–200.
9. Guevara-Silva EA. Cognitive impairment and antiretroviral treatment in a Peruvian population of patients with human immunodeficiency virus. Neurologia. 2014; 29(4): 224–9.
10.Sacktor N, Tarwater PM, Skolasky RL, et al. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology. 2001; 57(3): 542–4.
11. Cysique LAJ, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006; 66(9): 1447–50.
12. Robertson KR, Robertson WT, Ford S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004; 36(1): 562–6.
13. Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder-pathogenesis and prospects for treatment. Nat Rev Neurol. 2016; 12(4): 234–48.
14. Montreal CognitiveAssessment: Influence of Sociodemographic and Health Variables Sandra Freitas, Mário R. Simões, Lara Alves, Isabel Santana Archives of Clinical Neuropsychology, Volume 27, Issue 2, March 2012, Pages 165–175)
15. Monnig MA, Kahler CW, Lee H, et al. Effects of smoking and alcohol use on neurocognitive functioning in heavy drinking, HIV-positive men who have sex with men. AIDS Care. 2016; 28(3): 300–5.
16. Bryant VE, Kahler CW, Devlin KN, et al. The effects of cigarette smoking on learning and memory performance among people living with HIV/AIDS. AIDS Care. 2013; 25(10): 1308–16.
17. da Silva CM, Mendoza-Sassi RA, da Mota LD, Nader MM, de Martinez AMB. Alcohol use disorders among people living with HIV/AIDS in Southern Brazil: prevalence, risk factors and biological markers outcomes. BMC Infect Dis. 2017; 17(1): 263.
18. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, andpredictors. J Neurovirol. 2011; 17(1): 3–16.
19. Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008; 63(2): 213
20. Reger MA, Martin DJ, Cole SL, Strauss G. The relationship between plasma viral load and neuropsychological functioning in HIV-1 infection. Arch Clin Neuropsychol. 2005; 20(2): 137–43.
21. Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitiv eimpairment in the context of plasma HIV RNA suppression. J Neurovirol. 2011; 17(2): 176–83.
22. Heaton RK, Franklin DRJ, Deutsch R, et al. Neurocognitivechange in theera of HIV combinationantiretroviraltherapy: thelongitudinal CHARTER study. Clin Infect Dis. 2015; 60(3): 473–80.
23. S. Kamal, I. Locatelli, G. Wandeler et al. The presence of human immunodeficiency virus-associated neurocognitive disorders is associated with a lower adherence to combined antiretroviral treatment. Open Forum Infectious Diseases, vol. 4, no. 2, Article ID ofx070, 2017.
24. Koski L, Brouillette M-J, Lalonde R, et al. Computerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment. HIV Med. 2011; 12(8): 472–80.
25. Milanini B, Wendelken LA, Esmaeili-Firidouni P, Chartier M, Crouch P-C, Valcour V. The Montreal cognitive assessment to screen for cognitive impairment in HIV patients older than 60 years. J Acquir Immune Defic Syndr. 2014; 67(1): 67–70.
26. Overton E, Ances B, Grubb J, Parker N, Spitz T, et al. Novel screening tools for HIV-associated neurocognitive disorders; 18th Conference on Retroviruses and Infections (CROI); Washington Univ in St Louis, Sch of Med, MO, US. 2011
27. Mukherjee T, Sakthivel R, Fong HY, et al. Utility of using the Montreal cognitive assessment (MoCA) as a screening tool for HIV-associated neurocognitive disorders (HAND) in multi-ethnic Malaysia. AIDS Behav. 2018;10:1–8.